Gallic acid diminishes pro-inflammatory interferon-γ- and interleukin-17-producing sub-populations in vitro in patients with psoriasis

Psoriasis is an inflammation of the skin mediated via the IL-23/Thl17/IL-17 pathway. We have previously demonstrated that the anthocyanin delphinidin diminishes in vitro the IL-17 and IFN-γ production of peripheral monocytes isolated by psoriasis patients (PBMCs). The degradation product of delphinidin is gallic acid (GA). This phenolic acid compound found in fruits, red wine, or green tea exerts pleiotropic antioxidant, anticarcinogenic, antimicrobial, and anti-inflammatory properties. Previous research has demonstrated the inhibitory effect of GA on pro-inflammatory transcription factors, such as STAT3, RORγt, and NF-κB, or cytokines as IL-1β and TNF, which contribute to psoriasis development. We investigated the effect of GA in vitro on PBMCs, which were stimulated ex vivo, from 40 individuals (28 diagnosed with psoriasis vulgaris and 12 healthy controls (HCs)). In our experiments, PBMCs were cultured untreated or were activated in the presence of phorbol 12-myristate 13-acetate/ionomycin with or without GA. We utilized multicolor flow cytometry to assess the production of inteleukin-17 (IL-17) and interferon-γ (IFN-γ) in T and NK cells. GA did not alter the fractions of IL-17- or IFN-γ-producing T and IFN-γ-producing NK cells in HCs. However, in psoriasis patients, the effect of GA on that cell population was significant. Specifically, GA decreased the frequency of IL-17-producing cells within the CD3+ (T) and CD3+CD4+ (Th) compartment; the frequency of IFN-γ-producing cells within the CD3+, CD3+CD4+, and CD3+CD4− (Tc) compartment, and the frequency of IFN-γ-producing cells within the CD3−CD56+ (NK) compartment. Whether GA’s effect also appears in vivo needs to be investigated in future. Supplementary Information The online version contains supplementary material available at 10.1007/s12026-023-09361-9.


Introduction
Psoriasis is characterized by chronic inflammation of the skin. The interleukin (IL-)-23/T helper (Th) l17/IL-17 pathway has been recognized as crucial for the development of the disease. Skewing of CD4 + T cells towards a Th17 phenotype is in part mediated by tumor necrosis factor (TNF-) α and is characterized by signal transducer and activator of transcription 3 (STAT3) and retineic-acid-receptor-related orphan nuclear receptor gamma (ROR-γt) transcription factor upregulation [1]. Increased IL-17 production stimulates pro-inflammatory mediators in IL-17-R-bearing cell types, like keratinocytes. Another crucial component of the IL-17-mediated induction of psoriasis has been proposed to be nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB) [2]. Moreover, in psoriasis, additional cell subsets, like Th1 or Th1-like Th17, have been found in increased fractions compared to HCs [3]. Interferon-γ (IFN-γ), which is produced by such cell populations [4], has been suggested to induce a transcriptomic signature similar to that of psoriatic skin in unaffected skin [5].
We have previously demonstrated that delphinidin, which is an anthocyanin, effectively diminished in vitro IL-17 and IFN-γ production by phorbol 12-myristate 13-acetate (PMA)-activated peripheral blood mononuclear cells (PBMCs) isolated by psoriasis patients [6]. The degradation product of delphinidin has been found to be a phenolic acid, namely gallic acid (GA) [7,8]. GA is a phenolic acid compound [9], detected both free and as part of hydrolysable tannins, widely in fruits (i.e., pomegranate) and vegetables [10]. It is also found in red wine or green tea [11]. Biologic properties of non-flavonoid polyphenols such as phenolic acids, ranging from antioxidant, anticarcinogenic, to antimicrobial or anti-inflammatory, have been presented in numerous studies (reviewed by [12]). GA has also been examined for similar activities [13][14][15][16]. A plethora of patented applications of GA and its esters in medicine has been reported. Indeed, various properties in industry as an anti-oxidant, an anti-angiogenic, or a cosmetic agent have been attributed to GA [11]. Intriguingly, the anti-oxidant activity of GA, when compared to other known anti-oxidant compounds, has been reported to be one of the highest [17,18]. On the other hand, both GA and its esters have been reported to induce cell death in tumor cell lines [19,20] suggesting that GA may have both anti-oxidant and pro-oxidant capacities [13]. GA's anticancer activity has thus been investigated in many studies [21][22][23]. Further beneficial properties of GA include antimicrobial and anti-viral activities [13].
Based on the aforementioned observations regarding the significant in vivo or in vitro effect of GA, an investigation of the modulation of PBMCs isolated by psoriasis patients by GA was considered of particular interest. Of relevance to the present study, mounting evidence also supports the immunomodulatory and anti-inflammatory properties of GA. In murine models, researchers showed that GA treatment significantly inhibited NF-κB activation. Moreover, GA treatment compared to mock treatment resulted in lower levels of interleukin IL-1β and TNF-α expression in the small intestine and also lower levels of both cytokines in mouse sera [24]. Furthermore, in a murine chronic constriction injury model, GA reduced the levels of TNF-α, NF-kB, and phosphorylated STAT 3 (p-STAT3) in mouse sera [25]. Intriguingly, in an allergic rhinitis mouse model, GA treatment alleviated symptoms. Moreover, GA treatment suppressed levels of IL-17 and Th17 transcription factor, ROR-γt in the nasal lavage fluid [26]. The inhibitory effect of GA on pro-inflammatory molecules has also been investigated in vitro. Suppression of NF-κB phosphorylation has also been reported in LPS-challenged IPEC-J2 cell cultures when pre-treated with GA. Importantly, GA also abrogated TNF-α and IL-8 gene expression in IPEC-J2 cells [27]. In another study, poly (GA)-a compound enzymatically produced by GA-pre-treatment reduced IL-1β and IL-6 levels in supernatants of PMA-stimulated THP-1 cell cultures [28]. In A549 lung cancer cell cultures, GA treatment resulted in attenuated phosphorylation of both JAK and STAT3 [29]. In a HT-29 cell line culture that was challenged with human recombinant IL-17 and TNF-α, IL-17A expression was significantly suppressed when cells were co-cultured with GA [30].
In view of the above, we were interested to assess the in vitro effect of GA in an immune-mediated disease, using psoriasis as a reference disease. Due to the high instability of delphinidin, we intended to investigate whether the in vitro or in vivo anti-inflammatory effects exerted by delphinidin could potentially be expanded by the subsequent activity of GA after delphinidin's rapid degradation. Researchers have already supported that both delphinidin's metabolites and GA promote Treg differentiation when co-cultured with CD4 + naïve T cells isolated from mice [7]. However, the immunomodulatory effect of GA on PBMCs from individuals diagnosed with psoriasis has to our knowledge not been explored. The lack of sufficient information regarding this matter has led us to investigate by multicolor flow cytometry the effect of GA on IL-17 and/or IFN-γ expression by PMAstimulated PBMCs isolated by individuals with psoriasis and healthy controls (HCs).

Patients
Twenty-eight consecutive patients diagnosed with moderate to severe plaque psoriasis (Psoriasis Area Severity Index > 7) that attended the Outpatient Department of the Department of Dermatology of General University Hospital of Larissa and 12 HCs were enrolled in this study. Main demographic and clinical parameters of the enrolled participants are summarized in Table 1. Our patient cohort was consisted of 9 females and 19 males, with a mean age of 49 ± 10.6 years. In total, 8 individuals were naïve to any therapy, 5 were receiving conventional disease-modifying anti-rheumatic drugs, 7 were receiving apremilast, a PDE4 inhibitor, and 8 were receiving biologic agents (anti-IL-23, anti-IL-17) during blood sample collection. Clinical or radiological signs suggesting a psoriatic arthritis diagnosis were not apparent to any of the psoriasis patients. Written informed consent was signed by all subjects involved in this study, in accordance with the revised Declaration of Helsinki.

Chemicals
GA (purity ≥ 98%) was purchased from Cayman Chemical (Ann Arbor, Michigan, USA). PMA and ionomycin were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Brefeldin was obtained by GolgiPlug™, BD Biosciences. Each reagent was dissolved in dimethylsulfoxide (DMSO) and subsequently aliquoted to be stored at − 20 °C. However, final DMSO concentration never exceeded 0.1% in any cell culture experiment. Selection of the GA concentration used in this study was based on dose-response experiments utilizing GA at a concentration range from 5 to 100 μg/mL. Opted concentration was in accordance with published in vitro or in vivo studies on pharmacokinetics and bioavailability.

Peripheral blood mononuclear cell isolation and cryopreservation
Heparinized syringes were used to obtain peripheral blood samples (20 mL) by venipuncture. Layering over the surface of a discontinuous LymphoPrep gradient (Axis-Shield, Oslo, Norway) and subsequent centrifugation were utilized to isolate PBMCs from each blood sample. A protocol involving two washings of isolated PBMCs with RPMI 1640 (GIBCO™, Thermo Fisher Scientific, Waltham, MA, USA) was applied afterwards. Cells were then enumerated using a Neubauer hemocytometer. Moreover, cell viability was assessed for each sample by trypan blue exclusion dye and routinely surpassed 95%. A cell cryoprotective solution consisting of 10% DMSO, 30% RPMI 1640, and 60% fetal calf serum (FCS) was produced. PBMCs were then re-suspended in that medium and aliquoted into cryotubes (Corning™, Thermo Fisher Scientific, Waltham, MA, USA). Aliquots were kept at − 80 °C for 24 h, and then were stored in liquid nitrogen containers until further use.

Cell thawing
Cryotubes were removed from the liquid nitrogen containers and immediately transferred into a water bath of approximately 37 °C. Each cryotube stayed within bath for < 1 min and was subsequently transferred in a flow laminar hood. Cells and pre-warmed RPMI 1640 were simultaneously transferred dropwise in a centrifuge tube. Thawed PBMCs were then centrifuged for 5 min. Supernatant was afterwards decanted. Finally, PBMCs were re-suspended in a culture medium containing 10% FCS and 90% RPMI 1640.

Cell culture
PBMCs were seeded in 6-well culture plates (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany). In each well, 6 × 10 6 PBMCs were placed within 3 mL of the culture medium. PBMCs were incubated at 37 °C (5% CO 2 ). GA was added to PBMC culture 0.5 h prior to activation at an end concentration of 30 μg/mL. PBMCs were stimulated in the presence of PMA (50 ng/mL), ionomycin (1 μg/mL), and brefeldin A for 5 h. Cells that were not stimulated were used as controls, while cells supplemented only with GA were used as vehicle controls.

Flow cytometric phenotypic analysis
A Guava EasyCyte 8 (Merck-Millipore, Burlington, USA) benchtop flow cytometer was utilized to explore PBMC sub-populations. Assessment of cell phenotypes and enumeration of subsets was accomplished using standard antihuman fluorochrome-conjugated monoclonal antibodies targeting specific surface markers, as previously described [31]. Briefly, identification of T cell subsets involved use of fluorescein isothiocyanate-conjugated anti-CD3 (clone UCHT1), phycoerythrin (PE)-conjugated anti-CD56 (clone HCD56), and (PE-Cy7)-conjugated anti-CD4 (clone RPA-T4). All monoclonal antibodies were purchased by BioLegend (San Diego, CA, USA). Reagents used are listed in Online Resource 1. To wash cultured PBMCs, phosphatebuffered saline (PBS) was used. Re-suspension of isolated cells in staining buffer containing PBS + 1% FCS + 0.09% sodium azide followed. Viable cells (0.5-1 × 10 6 cells) were subsequently incubated with optimally titrated labeled antigen-specific monoclonal antibodies on ice for 30 min. Afterwards, paraformaldehyde (2%) was utilized for cell fixation. Logarithmic amplification was used, while lymphocytes were sub-gated based on forward and side light scatter characteristics. To accurately measure infrequent cell subsets, at least 3 × 10 5 events within the lymphocyte gate were collected. Both high background and false positive readouts were excluded based on isotype control monoclonal antibodies.

Flow cytometric viability analysis
To assess viability of PBMCs after thawing, each sample was stained with FICT-conjugated Annexin V (Bio-Legend, San Diego, CA, USA), which identifies apoptotic cells, per manufacturer's instructions. Cells were washed twice, and then were re-suspended in Annexin V Binding Buffer. PBMCs were subsequently incubated with optimally titrated Annexin V in the dark for 15 min. Finally, Annexin V Binding Buffer was added in each tube and each sample was analyzed with flow cytometry.

Statistical analysis
Descriptive statistical measures (mean and standard deviation (SD)) were used to describe cohort's characteristics. We presented surface-epitope expressing cell fractions as percentages and described them using a mean ± SD. To compare percentages regarding a specific cell subset between GA-treated and -untreated cells, a paired t-test or a Wilcoxon signed-rank test was used. Mean values and 95% confidence interval (CI) or median values of difference were used to describe differences between groups, depending on the type of comparison (parametric or nonparametric test used). To correlate changes in cell fractions between various cell sub-populations, Pearson correlation coefficient or Spearman's rank correlation coefficient was used. To assess the effect of therapy on GA-mediated inhibition of IFN-γ and IL-17 in various cell subsets, a simple linear regression was utilized. A p value of ≤ 0.05 was defined as significant. Statistical calculations were executed within Graphpad Prism software.

Results
The effect of various concentrations of GA on IL-17 and IFN-γ expression in PBMCs isolated by both participants with psoriasis (n = 28) and HCs (n = 12) was examined. Based on previous in vitro experiments involving GA of the literature, the final concentrations of GA tested were 5, 10, 30, 50, and 100 μg/mL for either 0.5 or 2 h. The strongest effect of GA on cytokine abrogation that was accompanied by cell viability preservation was observed in the presence of 30 μg/mL GA 0.5 h prior stimulation. Viability of cells at this concentration was maintained, while higher concentrations of GA diminished cell viability. The optimal concentration of GA for our experiments was thus considered to be 30 μg/mL (Online Resource 3). This concentration corresponds to that used for in vitro experiments using cell lines in published series [32][33][34]. PBMCs were effectively sub-gated utilizing both surface and intracellular staining. Figure 1 presents gating strategy used to analyze our data. Cell viability for each sample used was assessed after thawing of cells. Percentage of cells that were stained with Annexin V, which identifies apoptotic cells, was consistently ≤ 10%. GA treatment did not affect cell viability. CD3 + CD4 + and CD3 + CD4 − cell sub-population percentages were not affected by GA treatment. The CD3 + CD4 + and CD3 + CD4 − cell population percentages did not significantly differ between the GA-treated and -untreated PBMCs, as depicted in Online Resource 4.

GA in vitro pre-treatment diminished fractions of IL-17-producing CD3 + and CD3 + CD4 + PMA-stimulated cell subsets in psoriasis patients
We next explored the effect of GA treatment on the fraction of IL-17-producing PMA-activated cell subsets isolated from participants with psoriasis. Figure 2a,b presents representative plots from flow cytometry of GA-treated and -untreated cells that were activated with PMA and ionomycin. As shown in Fig. 2c, the percentages of IL-17-producing T and Th cells were significantly inhibited by in vitro GA pre-treatment. Specifically, the sub-population fractions of IL-17 + T and Th cells were diminished from mean = 0.78 (SD = 0.70) and mean = 0.89 (SD = 0.56) to mean = 0.29 (SD = 0.19) and mean = 0.35 (SD = 0.24), respectively, which corresponds to a decrease of 63% and 61%, respectively. IL-17 production within the CD3 + CD4 − compartment was not observed.

PMA-stimulated cell subsets in psoriasis patients
We also investigated the effect of GA treatment on the fraction of IFN-γ-producing PMA-activated cell subsets isolated from participants with psoriasis. Figure 3a presents representative plots from flow cytometry of GA-treated and -untreated cells

GA in vitro pre-treatment diminished fraction of IFN-γ-producing CD3 − CD56 + , PMA-stimulated cell subsets in individuals with psoriasis
We also investigated the effect of GA-treatment on the frequencies of IFN-γ expressing CD3 − CD56 + NK subset in PMA-stimulated PBMCs isolated from participants with. Figure 4a presents representative plots from flow cytometry of a psoriasis sample that was evaluated under GA-treated and -untreated PMA-stimulated conditions for IFN-γ production. As shown in Fig. 4b, IFN-γ production in NK cells that were activated by PMA and ionomycin was significantly inhibited by in vitro GA pre-treatment, from a mean = 36.67 (SD = 19.58) to a mean = 20.42 (SD = 12.21).

Level of GA-mediated inhibition on Th1 cells was correlated with the inhibition of Th17 and IFN-γ-producing NK cells in PMA-stimulated PBMCs isolated by psoriasis patients
We explored associations between levels of GA pre-treatment-induced inhibition of each cell subset fraction investigated in this study. Between GA-treated and -untreated cell cultures that were activated with PMA and ionomycin, a mean of change values was calculated for Th17, Th1-, Tc1-, and IFN-γ-producing NK cells. As depicted in Fig. 5, change in Th1 cell percentages after GA treatment was significantly correlated with change in percentage of Th17 (Pearson r = 0.42, p = 0.024) and of percentage of IFN-γ-producing NK cells (Pearson r = 0.45, p = 0.015). GA's activity may not accrue by an effect on a specific PBMC sub-population, but rather by a simultaneous inhibitory effect on various pro-inflammatory cell populations.

GA-mediated inhibition of IFN-γ production in CD3 + CD4 − cells is higher in PBMCs isolated by patients treated with biologic therapies
We investigated whether treatment received during sample collection affected the GA-mediated inhibition of IL-17-or IFΝ-γ-producing PBMC subsets. Participants diagnosed with psoriasis vulgaris were grouped into 3 categories: those naïve to treatment (n = 8), those receiving biologic therapy (n = 8), and those receiving non-biologic therapy (n = 12, DMARDs and apremilast). A simple linear regression was executed to assess the effect of therapy received during sample collection on the change in cell frequency between GA-treated and -untreated conditions for each cell subpopulation. The mean cell percentage difference between GA-treated and -untreated cells for each population was used as a dependent variable, while the treatment received was used as independent variable for each simple regression model. Therapy received did not affect the mean difference of Th17-, Th1-, and IFN-γ-producing NK cells between GA-treated and GA-untreated cultures (Online Resource 5). Regarding IFN-γ-producing CD3 + CD4 − cells, cells isolated from patients receiving biologic therapy showed a significantly higher decrease in IFN-γ production following GA in vitro treatment compared to those isolated by patients naïve to therapy for psoriasis vulgaris (Online Resource 5).

Discussion
To our knowledge, this is the first study to explore the effect of GA supplementation on Th17-, Th1-, and IFN-γ-producing NK cells in patients diagnosed with psoriasis vulgaris. We hereby present a remarkable decrease in the frequencies of the aforementioned PMA-stimulated cell subsets upon in vitro GA exposure. Interestingly, the sharp reduction in IFN-γ-producing cell percentages mediated by GA included Tc cells too. Our in vitro results clearly demonstrate direct effects of GA on proinflammatory cytokines, which remarkably are observed in psoriasis patients, but not in HCs. Whether GA affects cytokine production in a disease-specific manner remains to be explored in future studies enrolling both larger cohorts and other diseasecontrol patients. Nevertheless, we are confident that our data are significant, as the inhibitory effect of GA was consistent in all psoriasis patients tested, while lack of such an inhibitory effect was noted in every single healthy control assessed. Our data could be intriguing given that such a ramification noted in psoriasis patients but not in HCs was not evident in our previous in vitro study using the naturally GA-enriched compound of delphinidin. Fig. 2 Gallic acid (GA) in vitro pre-treatment diminished fractions of IL-17-producing T (CD3 + ) and Th (CD3 + CD4 + ) cell subsets that were stimulated by PMA/ionomycin in participants with psoriasis (n = 28) and controls (n = 12). Isolated peripheral blood mononuclear cells were co-cultured with PMA/ionomycin with or without GA. Cells were analyzed following GA pre-treatment for 0.5 h and PMA and ionomycin stimulation. a Representative plots from flow cytometry of GA-treated and -untreated IL-17-producing T and Th cells from patients. b Representative plots from flow cytometry of GAtreated and -untreated IL-17-producing T and Th cells from controls. c Boxplots (showing mean ± SD) depicting that IL-17-producing T and Th cells were significantly inhibited by in vitro GA pre-treatment in patients. ***p ≤ 0.001, ****p ≤ 0.0001 by Wilcoxon signed-rank test or paired t-test ◂ Fig. 3 Gallic acid (GA) in vitro pre-treatment diminished fractions of IFN-γ-producing T (CD3 + ), Th (CD3 + CD4 + ) and Tc (CD3 + CD4 − ) cell subsets that were stimulated by PMA and ionomycin in participants with psoriasis (n = 28). Isolated peripheral blood mononuclear cells were co-cultured with PMA/ionomycin with or without GA. Cells were analyzed following GA pre-treatment for 0.5 h and PMA and ionomycin stimulation. a Representative plots from flow cytometry of GA-treated and -untreated IFN-γ-producing T, Th, and Tc cells. b Boxplots (showing mean ± SD) depicting that IFN-γ-producing T, Th, and Tc cells were significantly inhibited by in vitro GA pre-treatment. ****p ≤ 0.0001 by Wilcoxon signed-rank test or paired t-test The GA-mediated decrease on IL-17-and IFN-γproducing cells provides indications that GA may be a compound of interest in any effort to explore new anti-inflammatory agents against the disease. IL-17 has long been characterized as the crucial cytokine in the pathogenesis of psoriasis [35]. High efficacy anti-IL-17 biologic therapies are used in the management of the disease [36]. The mechanisms responsible for the inhibitory effect of GA on IL-17 production by CD4 + cells are not clear. Transcription factor ROR-γt has been identified as a lineage defining factor of Th17 cells [37]. In nasal lavage fluid collected by ovalbumin-induced murine allergic rhinitis murine model, GA treatment suppressed levels of ROR-γt [26]. Furthermore, STAT3 has also been characterized as a Th17 transcription factor [38]. Inhibition of p-STAT3 has been reported to be mediated by GA [25,29]. Additional to the inhibitory effect of GA on IL-17 production, the compound has been reported to diminish the activity of IL-17-stimulated downstream signal transduction pathways. The cytokine-driven feed-forward loop facilitated in psoriasis is transduced by certain molecules, including NF-κB. Mutations in genes encoding activators of NF-κB have been associated with psoriasis development [39]. Interestingly, GA has been found to suppress NF-κB phosphorylation in LPS-challenged IPEC-J2 cell cultures [27].
We also observed an effect of GA pre-treatment on the percentage of IFN-γ-producing NK cells following PMA stimulation. GA significantly decreased the fraction of CD3 − CD56 + IFN-γ + cell subset. NK cells have been suggested to participate in the establishment of the inflammation loop of psoriasis [40]. Specifically, NK cells have been reported to accumulate in psoriatic skin and promote inflammation [41,42].
Of relevance, recent in vitro evidence suggests that GA inhibits additional immune pathways that are known to be actively involved in the disease. For example, IL-6 has been identified as a key cytokine that participates in proinflammatory mechanisms in skin and eventually leads to development of psoriatic skin lesions. In psoriatic skin, dendritic cells produce high levels of IL-6, which promotes escape from Treg suppression [43] and skewing of CD4 + T cells towards a Th17 phenotype [44]. GA has been shown to mediate inhibition of IL-6 production in IL-33-activated basophilic KU812 cells in vitro [45]. In another study, poly(GA) reduced IL-6 levels in supernatants of PMA-stimulated THP-1 cells [28]. Furthermore, dendritic cells produce TNF-α [46], a central molecule in the inflammatory milieu of psoriasis, which directly affects keratinocyte gene expression [47]. In murine models, GA treatment has been associated with decreased levels of TNF-α in mouse sera [24]. The effect of GA on immune cell populations has been partly investigated [9]. In a recent in vitro study, GA was shown to enhance Foxp3 + cells (iTreg differentiation when C57BL/6 mice spleen-isolated CD4 + T cells were co-cultured in the presence of GA with TGF-β and IL-2). Moreover, GA co-culture with iTregs suppressed Teff proliferation compared to cultures where GA was absent. In an in vivo study, intraperitoneal administration of GA in an allograft rejection mouse model expanded Tregs and decreased activated T cells [7]. In a murine model of arthritis, GA decreased local inflammation, and inhibited the in vitro release of neutrophil TNF-a [48]. Furthermore, in monosodium urate crystal stimulated swelling of joints in mice, GA mitigated symptoms and inhibited IL-1β expression [49]. In the human setting, GA treatment of fibroblast-like synoviocytes isolated from patients with rheumatoid arthritis increases the levels of pro-apoptotic caspase-3 and decreases the expression of pro-inflammatory molecules in vitro [50]. Whether GA's immunoregulating activity could also be exploited for the management of inflammatory joint diseases remains to be seen, but early in vitro or in vivo data suggest that such a probability should not be underestimated.
In our study, GA-mediated inhibition of IFNγ production was significantly higher in CD3 + CD4 − T cells isolated from patients receiving bDMARDs compared to PBMCs isolated from treatment-naïve patients. A synergistic effect of GA with biotechnological drugs has been documented. In a melanoma-bearing mouse model, combination of GA and an IDO inhibitor exerted an in vitro effect in CD8 + and Tregs [51]. An in vitro combined effect of GA with doxorubicin was stronger in suppressing growth of DU145 prostate cancer cells [52] and the combined effect was also noted in human squamous carcinoma [53] and glioma cell lines [33]. To our knowledge, our in vitro study is the first to indicate an indirect synergistic effect of GA with a bDMARD. A hypothesis regarding the molecular mechanisms that could explain such a synergism could be formed. While bDMARDs inhibit the end product of the pro-inflammatory feed-forward loop, such as IL-23 or IL-17, GA has been reported to inhibit NF-κB and STAT3, and thus effectively decrease the proportion of pro-inflammatory cells such as the circulating Th17 cells. As shown in this study, GA inhibits the proportion of PBMCs producing IFNγ and IL-17. GA has also been suggested to have high binding affinities with the receptors of INF-a2, IL-4, and IL-6 [54]. Our in vitro approach prevented us from speculative arguments that could exploit this further but future research will shed a light in revealing such a possible synergism.
In our study, GA's inhibitory effect on PBMC pro-inflammatory subpopulations was significant in patients with psoriasis and not in HCs. Our data cannot provide a mechanistic elucidation for such a finding. We could only hypothesize that the selective effect of GA in activated PBMCs is mediated by STAT3 and/or NF-κB hyperactivation; STAT3 hyperactivation significantly contributes to cytokine production and lesion development in patients with psoriasis [55], and GA is able to inhibit phosphorylation of STAT3. A "STAT3 hyperactivated state" in patients with psoriasis but not in HCs may account for the exerted inhibitory effect of GA and that may also be the case for NF-κB. Both molecules have been targeted in the past for the management of the disease [56]. Such speculative scenarios must be addressed experimentally in vitro and in vivo.
Whether GA could be utilized as a therapeutical agent against psoriasis or as a supplement to conventional treatment needs to be determined in proper in vivo studies and well-designed randomized control clinical trials. Important tackles to overcome relate to the absorption and Gallic acid (GA) in vitro pre-treatment diminished percentages of Th17-, Th1-, and IFN-γ-producing NK cell subsets that were stimulated by PMA/ionomycin in participants with psoriasis (n = 28). Isolated peripheral blood mononuclear cells were co-cultured with PMA/ionomycin with or without GA. Cells were analyzed following GA pre-treatment for 0.5 h and PMA and ionomycin stimulation. a GA-mediated inhibition on the IFN-γ-producing Th cell percentage was correlated with the inhibition of the fraction of IL-17-producing Th cells. b GA-mediated inhibition on the IFN-γ-producing Th cell percentage was correlated with the inhibition of the fraction of IFNγ-producing NK cells bioavailability characteristics of GA. A few studies have investigated the absorption and bioavailability characteristics of GA. Orally administered concentrated tea brew (about three times concentrated compared to normal tea brew) in individuals led to a maximum plasma GA concentration of 2 μmol/L after approximately 1 h of tea consumption [57]. The reported relatively low plasma concentration is of limited relevance (up to 80 times lower) to the concentration used in our in vitro study, suggesting that the observed effects on PBMC subsets could result from bioenhanced pharmacologically relevant GA concentrations in order to be of clinical significance. The relatively low plasma concentrations achieved from oral compounds may limit its therapeutic potential. Such limitations have been observed in other diet supplements such as curcumin and led to the development of more bioactive formulas. Repeated dosing [58], usage of phospholipid complexation [59], or colloidal delivery system development [9] as a way to enhance the therapeutic effect of GA have also been investigated with favorable results. Finally, the biological effects of GA may be hampered by the rapid metabolism in humans. Poor stability and solubility may also explain the observed inconsistent oral bioavailability of GA [9].
GA appears to be very safe and significant issues regarding its toxicity have not been raised. Acute toxicity of GA is reported; only enormous doses are administered in mice (≥ 2000 mg/kg) [60]. No adverse events were observed in F344 rats fed with 120 mg/kg/day for 13 weeks [61]. Furthermore, in a murine model of pelvic inflammatory disease, administration of 210 mg/kg had no toxic effect [62]. In another study investigating the toxicity of GA, researchers reported that even high doses of up to 900 mg/kg/day GA for 28 days were not toxic [63]. Based on these results, GA's administration could be evaluated as clinically relevant, since toxicity is reported only in extremely high doses. Nevertheless, toxicity and safety issues of more bioactive formulas must be assessed.
We consider that our results could constitute the impetus for future in vitro or in vivo studies that assess the pharmaceutical effect of GA in any form-ranging from the dietary intake to orally supplemented GA as a concentrated compound or even to topically applied creams or lotions containing GA alone or in conjunction to other anti-inflammatory agents-on psoriatic lesions.